Valeant
Inside the lawsuit against the maker of Cold-fX
A Q&A with the lawyer who alleges Valeant, the maker of Cold-fX, misled consumers about the short-term effectiveness of the cold and flu remedy
A surefire made-in-Canada way to lose $650 billion
Here’s a stock tip Valeant investors should have heeded: If a company that’s not a bank becomes the largest in Canada, run!
Assume the crash position: How far will the stock market fall?
Canada’s stock market has suffered through a lost decade of returns. Why the bad times for Canadian investors could continue.
Why the world needs short sellers
In a market where so many have a vested interest in pumping up stock prices, short sellers serve as a necessary, if unwelcome, reality check
There’s no love lost between Canadians and the stock market
Canadians have found something else to be emotionally and financially invested in: real estate
On Toronto’s stock exchange, it’s not always great being in first
The biotech giant Valeant is now at the top of the heap in Canada. Will it succumb to the curse of being the biggest company in the land?